REVEX Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Revex, and when can generic versions of Revex launch?
Revex is a drug marketed by Hikma and is included in one NDA.
The generic ingredient in REVEX is nalmefene hydrochloride. There are four drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the nalmefene hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Revex
A generic version of REVEX was approved as nalmefene hydrochloride by PURDUE PHARMA LP on February 8th, 2022.
Summary for REVEX
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 41 |
Patent Applications: | 5,367 |
Formulation / Manufacturing: | see details |
DailyMed Link: | REVEX at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for REVEX
US Patents and Regulatory Information for REVEX
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Hikma | REVEX | nalmefene hydrochloride | SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS | 020459-001 | Apr 17, 1995 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Hikma | REVEX | nalmefene hydrochloride | SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS | 020459-002 | Apr 17, 1995 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |